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Abstract
Objectives. To determine changes in out-of-pocket expenditure on prescription medicines for Australian patients,
and how patient expenditure compares with other Organisation for Economic Co-operation and Development (OECD)
countries.
Methods. We examined out-of-pocket expenditure on prescription medicines by patients in Australia between 1970
and 2007, and between Australia and 15 other OECD countries (Canada, Czech Republic, Denmark, Finland,
France, Germany, Japan, Republic of Korea (South Korea), Luxembourg, Poland, Slovak Republic, Spain, Sweden,
Switzerland and the United States) in 2005.
Findings. Spending on publicly subsidised medicines by Australian patients increased from $16 per person in 1971 to
$62 in 2007. Patient expenditure on all prescription medicines had risen to $134 per person in 2007. Out-of-pocket
expenditure for Australian patients ranked 4th of 14 OCED countries with universal pharmaceutical subsidies. Australian
patients pay 28%of national pharmaceutical expenditure; more than patients in SouthKorea (27%), SlovakRepublic (26%),
Sweden (22%), France, Luxembourg, Japan and Switzerland (17%), Germany (15%), Czech Republic (11%) and Spain
(6%), but less than patients in Finland (36%), Denmark (33%) and Poland (34%).
Conclusions. Compared to other OECD countries, Australian out-of-pocket costs are now in the mid to upper range.
Further increases have the potential to significantly affect access to care.
What is known about the topic? In Australia and internationally, increases in the portion of prescription medicines paid
by patients have been associated with falls in utilisation. Despite the pharmaceutical subsidies patients receive under the
Australian Pharmaceutical Benefits Scheme, prescriptionmedicine costs are a barrier to access formany low income, elderly
and other vulnerable patients.
Whatdoes thispaperadd? Thefindingsdemonstrate that theprescriptionmedicine expenditure ofAustralian patients has
increased substantially over recent years, and is double that indicated by benefit-paid data alone. Out-of-pocket expenditure
in Australia is moderate-to-high by international standards.
What are the implications for practitioners? Patient out-of-pocket expenditure for prescription medicines in Australia
has increased in recent decades, accounting for higher proportions of household and national medicine expenditure. Lack
of patient involvement in treatment decisions is associated with patients forgoing medicines due to costs. Practitioners
are encouraged to discuss treatment decisions, cost-barriers and possible strategies to overcome cost-barriers with their
patients.
Additional keywords: international comparison, pharmaceutical expenditure, private expenditure.
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Background
Across industrialised countries, pharmaceutical expenditures
have increased rapidly over recent decades.1–3 These increases
have been attributed to ageing populations, the development of
new and expensive drugs, and the increasing use of pharmaceu-
ticals in managing chronic disease.4,5 In Australia, public expen-
diture under the Pharmaceutical Benefits Scheme (PBS) rose
by ~11% per annum throughout the late 1990s and 2000s,
reaching AU$7 billion in 2007–08.6 There has been much public
discussion about whether this scheme is becoming too expensive
and how to best ensure that the scheme remains affordable for
the community, and less about out-of-pocket costs for individual
patients andwhether these costs are affordable.7–9 In recent years,
a series of PBS policy changes has increased the proportion of
medicine costs borne by patients. Patient co-paymentsA were
increased by 24% in January 2005 and the safety-net thresholdB
has increased by the equivalent of eight prescriptions since
January 2006. The 2006 introduction of the safety net ‘20-day
rule’10,C has reduced the number of patients eligible for cheaper
medicines towards the end of the calendar year.11 There is
growing evidence that many Australian patients are struggling
to afford their prescribed medicines.3,11,12
Comparisons are often made with other Organisation for
Economic Co-operation and Development (OECD) countries
when determining whether public and patient medicine expen-
diture in Australia is sustainable.5,13,14 Patients’ out-of-pocket
spending (‘private expenditure’) on prescription medicines is
affected by the pharmaceutical subsidy systems which provide
coverage. Subsidy arrangements vary considerably between
countries, with public, private and mixed systems operating
across OECD nations. Despite the large differences in national
wealth across OECD countries, all have special pharmaceuticals
subsidy arrangements in place for their low income and other
vulnerable populations (Table 1).
This study examines private expenditure on prescription
medicines in Australia over the previous three decades,
and compares the current out-of pocket prescription medicine




Data were sourced from: (i) the Australian Institute of Health and
Welfare (AIHW) data cubes15; (ii) annual reports from the
AIHW’s ‘Health Expenditure Australia’ series13,14,16; and (iii)
the 2008 release of the OECD’s Health Data statistics.17 The
AIHW data cubes contain Australian public and private health
expenditure statistics dating back to 1960. These data do not
capture private expenditure for all prescription medicines in
Australia, only publicly subsidised prescription medicines. Pub-
lic subsidies are paid for PBS-listed medicines which cost
more than the patient contribution (co-payment) for a given
beneficiary group; currently $5.40 for concessional beneficiaries
and $33.30 for general beneficiaries.18 PBS medicines priced
below these co-payments are not subsidised, and the expenditure
data related to these prescriptions are not captured in the ‘benefit-
paid’ data. The completeness of these data have changed over
time as the general co-payment amount, and the number of
patients eligible for concessional benefits, has changed.5 Prior
to 1986, the co-payment for general beneficiaries was sufficiently
low that virtually all prescriptions were subsidised and
therefore captured in the benefit-paid data.19 In November
1986 the general co-payment was doubled from $5 to $10.
Following this, and all subsequent co-payment increases, some
PBSmedicineswere no longer captured in the benefit-paid data.19
Between 1990 and 2007 the benefit-paid statistics have only
captured an average of 81% of the PBS prescriptions dispensed
nationally.20–23
The AIHW data also provide statistics on ‘other’ pharmaceu-
ticals, which is an aggregate expenditure for over-the-counter
(non-prescription) medicines and private (non-PBS) prescrip-
tions as well as prescription medicines below the PBS co-pay-
ments.15 Annual AIHW reports provide expenditure estimates
specifically for under co-payment and private prescriptions.
These reports allow total private expenditure to be calculated
for all prescription medicines dispensed in Australia for the years
2004–07.13,14,16
The 2008 OECDHealth Data statistics include health system,
healthcare consumption and economic indicators for the 30
OECD member countries. Data are intermittent for the years
1960–70 but were collected annually from 1971. Some data are
not available for all countries in all years. The primary indicator of
interest in this study was private expenditure on prescription
medicines. These data are not collected in all countries, and some
countries’ records do not distinguish between private expenditure
on prescription and over-the-counter medicines.
Analysis
We examined changes in public and private expenditure on
prescription medicines in Australia between 1971 and 2007.
To adjust for changes in population size and inflation, we
compared per capita real expenditure converted to 2007–08 gross
domestic product (GDP) price levels.15 We calculated the
proportion of all national prescription medicine expenditure
paid privately, and the proportion of household expenditure
directed towards prescription medicines between 1971 and
2007.
We compared private expenditure on prescription medicines
inAustraliawith that in 15 otherOECDcountries; Canada, Czech
Republic, Denmark, Finland, France, Germany, Japan, Republic
of Korea (South Korea), Luxembourg, Poland, Slovak Republic,
Spain, Sweden, Switzerland and the United States (US) in 2005,
APatient contribution toward the cost of each prescription.
BOnce an annual threshold has been spent onPBSmedicines, a ‘safety net’ comes into effect,whereby subsequent prescriptions for the calendar year are dispensed
for a reduced co-payment to general beneficiaries and free to concessional beneficiaries.
CThe normal supply of repeat PBS medicines is for 30 days of treatment.
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Table 1. Characteristics of pharmaceutical subsidy schemes across Organisation for Economic Co-operation and Development (OECD) countries






Australia $35 952 Yes * Fixed co-payments
* Co-payment up to $21 per item, with contributions reduced to $3.30A per item after
$732 is spent annually18
* Low income patients, aged pensioners and social security recipients pay up to $3.30
per item, with a cost ceiling of $187 annually18
Canada $36 814 No30 * Co-payments, cost ceilings and special subsidy groups vary by province and private
insurer30
Czech Republic $22 042 Yes * At least one drug for each condition is fully subsidised (often a generic or the lowest-
cost branded item)
* For more expensive items, patients pay the difference between the subsidised-item
cost and the prescription cost31
Denmark $35 218 Yes * Capped proportional co-payments
*Patients pay all prescription costs up to $59 annually, then 50%of costs between $59
and$140,25%ofcostsbetween$140and$326, and15%ofcostsbetween$326and
$420. Medicines are free after costs exceed $420 annually32
Finland $32 728 Yes * Fixed and proportional co-payments
* Patients pay the fixed amount of $9.70 for most chronic disease medicines33,34
* Patients pay $9.70 plus 50% of the remaining cost for other medications33
France $31 048 Yes * Proportional co-payments
* Medications for life-threatening conditions and chronic diseases are free35–37
* Patients pay 35% of cost for most other drugs35,37
Germany $31 949 Yes * Capped proportional co-payments
* Patients pay 10% ofmedicine cost, withminimum charge of $5.70 andmaximumof
$11.40.38 The annual cost ceiling is 2% of the patient’s gross income.
* Low income patients and the chronically ill have costs capped at $94 annually38
Japan $32 002 Yes * Proportional co-payments
* Patients pay 30% of medicine cost
* Children and the elderly pay 10–20% of medicine cost36
Republic of Korea (South Korea) $23 038 Yes * Proportional co-payments
* Patients pay 30% of all pharmaceutical and medical costs up to $3937 annually
Luxembourg $59 176 Yes * Proportional co-payments
* Medicines for serious or chronic illnesses are free39
* Patients pay 20% of cost for most other drugs39
Poland $14 674 Yes * Proportional co-payments
* Patients pay either 0, 50, 70 and 100% of the medicine cost depending on the
therapeutic class
* Essential medicines are fixed at US$1.3040
* War veterans and the chronically ill have additional subsidies or free medicines
Slovak
Republic
$17 584 Yes * Free dispensing of essential medicines (generally cheapest available in therapeutic
class)
* Partial reimbursement of essential medicines which are priced higher than reference
meds capped at 20% of cost, or full cost for discretionary treatments
Spain $29 383 Yes * Proportional co-payments
* Patients pay 10% of the costs for chronic disease medicines
* Patients pay 40% of the cost for most other medications
* The elderly and social security recipients are exempt from co-payments
* The chronically ill have a cap of $3.50 per prescription41
Sweden $34 870 Yes * Capped proportional co-payments
*Patients pay allmedicine costs up to $120 annually, then between10–50%of costs to
a maximum of $240, after which medicines are free.36,41,42
Switzerland $38 119 Yes * Proportional co-payments
* Patients pay 10% of drug costs
United States $43 864 No * Varies by state and private insurer (Centers for Medicare and Medicaid Services,
US Department of Health and Human Services, see http://www.cms.hhs.gov/,
accessed 25 July 2011)
* Some low income earners eligible for Medicaid.
* Medicare D offers a range of schemes with varying co-payments and ceilings
(http://www.cms.hhs.gov/)
* End-stage renal patients are eligible for Medicare (http://www.cms.hhs.gov/)
AAll prices in $US using purchasing power parities for 2005.
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the most recent year when data from all countries were available.
To allow comparison between currencies, per capita expenditure
on prescription medicines were converted into $US using the
OECD’s purchasing power parity (PPP) exchange rates.24 PPPs
account for price differences across a range of goods and services
between countries and aremore reliable and stable than exchange
rate conversions.24 The OECD caution that PPPs are constructs
rather than exact values25 and that small differences in per capita
expenditure between countries should not be interpreted as
economically or statistically significant. They recommend that
countries be grouped according to their per capita wealth rather
than strictly ranked.25 Consistent with OECD recommendations
on groupings, we compared the per capita prescription medicine
expenditure of high income (Luxembourg, Switzerland and
the US), high–middle income (Australia, Canada, Denmark,
Finland, France, Germany, Japan and Sweden), low–middle
income (Czech Republic, South Korea and Spain), and low
income countries (Poland and the Slovak Republic).25
We also compared private expenditure on prescription med-
icines in Australia with 15 other countries as a proportion of total
national prescriptionmedicine expenditure and as a proportion of
household consumption expenditure in 2005. Household con-
sumption expenditure literally refers to total household spending
of goods and services and is included in the OECD Health
Statistics.17
Results
Private expenditure in Australia
Prescription medicine expenditure in Australia has increased
substantially over the past three decades, even after accounting
for inflation and population growth (Fig. 1). Private spending on
benefit-paid prescription medicines increased steadily in real
terms throughout the 1970s and 1980s, but has tripled since
1991, rising from an average ofAU$19 to $62 per person in 2007.
Private spending on all prescription medicines reached $134 per
person by 2007.
Patient spending accounted for ~22% of benefit-paid expen-
diture in the 1970s and 1980s and ~16% through the 1990s and
2000s (Fig. 2). These data do not capture all PBSmedicines after
1986, when some medicines began falling below the general co-
payment. When expenditure on private prescriptions and those
under co-payment is included, patient contributions account for
28% of national prescription expenditure. Fig. 3 shows private
expenditure on prescription medicines as a proportion of house-
hold consumption expenditure, in 2007 GDP prices. In the 1970s
and 80s Australian patients used ~0.1% of their household
expenditure for benefit-paidmedicines.This proportion increased
rapidly after the late 80s, despite some medicines falling out of
data-capture during this time, and by2006 reached 0.2%. In 2006,
the total proportion of household expenditure used for all pre-
scription medicines in Australia was 0.43%.
Private expenditure across OECD countries
We compared private per capita expenditure on prescription
medicines in Australia with 15 OECD countries (see Fig. 4). In
2005, Australian patients spent US$84 per capita on prescription
medicines. This positioned Australia as equal 6th highest of 16
OECD countries with available private expenditure data. Per
capita private expenditure was higher for patients in the United
States ($487), Canada ($262), Finland ($120), France ($103) and
the Slovak Republic ($95), compared with Australia.
We compared the proportion of national prescription
medicine expenditure paid by patients in each of the countries
with available data (Fig. 5). More than one quarter (28%) of
prescription medicine costs in Australia are privately financed,
placing Australia in the middle of the 16 OECD countries and
4th highest of the countries with universal pharmaceutical sub-
sidies. Australian patients pay for a higher proportion of national





























































Fig. 1. Public and private expenditure per capita on prescription medicines in Australia (2007 GDP price
levels). (a) Data sourced from the Australian Institute of Health and Welfare (AIHW) data cubes.15 (b) Data
sourced from the AIHW’s ‘Health Expenditure Australia’ reports.13,14,16
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Slovak Republic (26%), Sweden (22%), France, Luxembourg,
Japan and Switzerland (17%), Germany (15%), Czech Republic
(11%) and Spain (6%), but less than patients in Finland (36%),
Denmark (33%) and Poland (34%).
Compared to other high–middle income countries, Austra-
lians spend a moderate proportion of their household income on
prescription medicines (0.4%) (Fig. 6). This proportion is
consistent with the proportions of income spent in Denmark,
Japan and Sweden. Proportionate to household income, spending
was twice as high for patients in Finland (0.8%) and more than
three times as high in Canada (1.4) and the US (1.7%). However,
substantially lower portions of national expenditure were in-
curred by patients in the Czech Republic (0.3%), Germany
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Fig. 2. Percentage of total prescription medicine expenditure paid privately in Australia (2007 GDP price
levels). (a) Data sourced from the Australian Institute of Health and Welfare (AIHW) data cubes.15 (b) Data























































Private: benefit paid Private: all prescriptions
a 
b 
Fig. 3. Percentage of household consumption expenditure used for prescription medicines in Australia,
1971–2006. (a)Data sourced from theAustralian Institute ofHealth andWelfare (AIHW)data cubes.15 (b)Data
sourced from the AIHW’s ‘Health Expenditure Australia’ reports.13,14,16
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Discussion
Patient spending on prescription medicines has increased
substantially in Australia over the past three decades. Private
expenditure on benefit-paid medicines tripled between 1991 and
2007. During the same period, expenditure on other essentials,
such as food and electricity and gas, increased by much smaller
margins (66 and 121% respectively).26 Although the benefit-
paid statistics are available for every year in Australia since
1971, these data are not complete and underestimate patient
expenditure after 1986. Many high-volume medicine groups,
including antibiotics, antidepressants, anxiety medications, met-
formin and oral contraceptives are priced below the general
beneficiary co-payment, and are not captured in the benefit-paid
statistics.27 This represents a critical gap in data availability over
the past 24 years. Although the benefit-paid component of private
spending showed little increase after the January 2005 co-pay-
ment increase, private expenditure on all prescription medicines
actually increased from $97 to $123 per person in that year.
From 2004 to 2006, the proportion of all prescription medicine
expenditure borne by patients increased from 25 to 28%, and the
proportion of household expenditure used for medicines rose
from 0.34 to 0.43%.
The international data suggest that patient out-of-pocket
expenditure in Australia is nowmoderate to high. Australia ranks
in themiddle (6th of 16) of theOECDcountries in terms of patient
expenditure, and 4th of 14 countries with universal pharmaceu-
tical subsidies. It is unsurprising that per capita private spending
would be substantially higher in the US and Canada given their
largely private pharmaceutical insurance systems. Although
Canada’s GDP/per capita is similar to Australia’s, the lack of
universal pharmaceutical cover inCanada likely accounts forwhy
Canadian patients pay almost twice as much towards their
national medicine costs compared to Australian patients (53 v.
28%).
Australian patients do not face the highest prescription costs
in the OECD, but their expenditure is in the mid to upper range
for countries with universal pharmaceutical coverage. Recent
data suggests than many Australian patients are at the limit of
what they can afford to pay for medicines. Two international
surveys have reported that in 2007, 13%3 of Australian adults,
and in 2008, 20%28 of Australian adults in poor health, reported
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Fig. 4. Private expenditure on prescription medicines per capita across
OECD countries with different national incomes, 2005. Data was sourced










































Fig. 5. Percentage of national prescription medicine expenditure paid
privately across OECD countries with different national incomes, 2005.
Data were sourced from the OECD17 for all countries except Australia,
with data sourced from the AIHW.13
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because of cost (Fig. 7). The rates of underuse due to cost
reported by Australian patients in these studies were only
second to those reported by US patients and higher than those
in Canada,3,28 France28 and Germany.3,28 Australian studies
have reported that dispensings of selected essential medicines
including statins, proton-pump inhibitors, non-aspirin antiplate-
lets and osteoporosis treatments have decreased significantly
following the 2005 co-payments increase and subsequent safety
net policy changes.11,29
Limitations
The expenditures reported here are national-level and therefore
represent estimated per capita expenditure for the ‘average’
patient. Clearly, prescription medicine expenditure will vary
according to the health status, comorbidities and socio-economic
status of individual patients. Some patients will face higher cost
burdens than are reflected by these national estimates. There are
also limitations with the use of PPPs to compare pharmaceutical
expenditure across countries. Although PPPs are preferable to
volatile exchange rates, they are based on the price of a range of
goods and services.25 Healthcare or pharmaceuticals specific
PPPs would be a more accurate unit of exchange. These
conversion rates are currently under development by the
OECD.25 A further limitation is the incompleteness of the OECD
database.Data on private prescriptionmedicine expenditurewere
not available from the countries with national wealth and public
subsidy systems most similar to Australia (i.e. Italy, Iceland, the
Netherlands, New Zealand and the United Kingdom).
Our analysis has not accounted for patient expenditure on
non-prescription medicines. Available data indicated that Aus-
tralians spent $146 per person on non-prescription medicines in
2005; however, these data do not differentiate between spend-
ing on over-the-counter medicines and medical non-durables (i.
e. bandages and condoms).13,17 Cross-country comparisons of
non-prescription medicine expenditure are also difficult due to
differences in the way non-prescription medicines data are
captured and defined.2 Given these data limitations, we have
not reported non-prescription medicine expenditure. However,
we acknowledge that the true cost burden of medicines is likely
to be much higher than indicated by our analyses of prescrip-
tion medicines alone. The burden of prescriptions would also
be higher for many patients if the PBS safety net was not in
place.
The cross-county data discussed here are based on current
(2005) expenditures, and the relative ranking of countries may
change in the future. Of the 16 countries we examined, 4 have
fully proportional systems (Japan, South Korea, Spain and
Switzerland), 4 have capped proportional co-payments
(Denmark, Finland, Germany and Sweden,), 5 have proportional
co-payments in conjunction with ‘free lists’ (Czech Republic,
France, Luxembourg, Poland and Slovak Republic), 1 has fixed
co-payments (Australia) and 2 have mixed systems (Canada
and the US). These systems may respond differently to future
increases in medicines expenditures, and the effects on patient
expenditures across countries may be varied.
Conclusion
Thefindings from this study indicate thatAustralian patients have
faced increasing prescription medicines costs over recent years
and that patient expenditure is now in the middle to upper range
with comparable countries. Further large increases in the portion
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Fig. 6. Proportion of household consumption directed towards prescription
medicines across OECD countries with different national income. Data were
sourced from theOECD17 for all countries exceptAustralia,with data sourced
from the AIHW.13







General sample Sicker adults
Fig. 7. The proportion of adults reporting they had recently skipped doses of
medicine or not filled a prescription because of cost in five OECD
countries.3,28
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substantially affect access to and use of prescribed medicines,
with potential risks to patient health andwellbeing. Policymakers
should consider the ongoing affordability ofmedicine to patients,
as well as to the wider community, when reviewing pharmaceu-
tical reimbursement policy.
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